University of Groningen
Evaluation of renal end points in nephrology trials
Weldegiorgis, Misghina Tekeste
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2017
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Weldegiorgis, M. T. (2017). Evaluation of renal end points in nephrology trials. University of Groningen.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Evaluation of renal end points in
nephrology trials
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. dr. E. Sterken
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Wednesday 8 November 2017 at 16.15 hours
by
Misghina Tekeste Weldegiorgis born on 27 February 1986
in Harer, Ethiopia
Evaluation of renal end points in
nephrology trials
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. dr. E. Sterken
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Wednesday 8 November 2017 at 16.15 hours
by
Misghina Tekeste Weldegiorgis born on 27 February 1986
Financial support for the printing of this thesis was kindly provided by the University of Groningen, University Medical Center Groningen, and Graduate School for Drug Exploration (GUIDE).
© Misghina Tekeste Weldegiorgis, Groningen, the Netherlands 2017 Cover design: Nynke Visser
Layout: Misghina T. Weldegiorgis
Printed by: GVO drukkers & vormgevers B.V ISBN: 978-94-034-0154-6 (printed version)
978-94-034-0153-9 (digital version)
Copyright by Misghina Tekeste Weldegiorgis, Groningen, the Netherlands. All rights reserved. No part of this publication may be reproduced, stored on a retrieval system, or transmitted in any form by any means, without permission of the author.
Financial support for the printing of this thesis was kindly provided by the University of Groningen, University Medical Center Groningen, and Graduate School for Drug Exploration (GUIDE).
© Misghina Tekeste Weldegiorgis, Groningen, the Netherlands 2017 Cover design: Nynke Visser
Layout: Misghina T. Weldegiorgis
Printed by: GVO drukkers & vormgevers B.V ISBN: 978-94-034-0154-6 (printed version)
978-94-034-0153-9 (digital version)
Copyright by Misghina Tekeste Weldegiorgis, Groningen, the Netherlands. All rights reserved. No part of this publication may be reproduced, stored on a retrieval system, or transmitted in any form by any means, without permission of the author.
Evaluation of renal end points in
nephrology trials
PhD thesis
to obtain the degree of PhD at the University of Groningen
on the authority of the Rector Magnificus Prof. dr. E. Sterken
and in accordance with the decision by the College of Deans. This thesis will be defended in public on Wednesday 8 November 2017 at 16.15 hours
by
Misghina Tekeste Weldegiorgis born on 27 February 1986
Promotors: Prof. Dr. D. de Zeeuw
Prof. Dr. H.J. Lambers Heerspink
Assessment Committee: Prof. Dr. B. Flamion Prof. Dr. S. J. L. Bakker Prof. Dr. R.T. Gansevoort Promotors
Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw Assessment Committee Prof. dr. R.T. Gansevoort Prof. dr. S.J.L. Bakker Prof. dr. H.G.M. Leufkens Promotors
Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw Assessment Committee Prof. dr. R.T. Gansevoort Prof. dr. S.J.L. Bakker Prof. dr. H.G.M. Leufkens Promotors
Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw Assessment Committee Prof. dr. R.T. Gansevoort Prof. dr. S.J.L. Bakker Prof. dr. H.G.M. Leufkens Promotors
Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw Assessment Committee Prof. dr. R.T. Gansevoort Prof. dr. S.J.L. Bakker Prof. dr. H.G.M. Leufkens Promotors
Prof. dr. H.J. Lambers Heerspink Prof. dr. D. de Zeeuw Assessment Committee Prof. dr. R.T. Gansevoort Prof. dr. S.J.L. Bakker Prof. dr. H.G.M. Leufkens Paranymphs: K.P.J. Smits S.T. de Vries
Paranymphs: K.P.J. Smits S.T. de Vries
Table of contents
Chapter 1 Introduction and aim of the thesis 8 Adapted from Current Opinion in Nephrology and Hypertension 2015 May;24(3):284-9
Chapter 2 Progressive renal function loss, a straight line? Longitudinal eGFR 19 trajectories in patients with and without type 2 diabetes and nephropathy American Journal of Kidney Diseases, In Press
Chapter 3 Slope of glomerular filtration rate as clinical trial end point 46 Submitted
Chapter 4 Estimated GFR decline as a surrogate end point for kidney failure 59 American Journal of Kidney Diseases 2014 Feb;63(2):244-50
Chapter 5 Is chronic dialysis the right hard renal end point to evaluate 80 renoprotective drug effects?
Clinical Journal of the American Society of Nephrology, In Press
Chapter 6 Summary and future perspectives 99
Nederlandse samenvatting en toekomstperspectief 107
Acknowledgments 116
Table of contents
Chapter 1 Introduction and aim of the thesis 8 Adapted from Current Opinion in Nephrology and Hypertension 2015 May;24(3):284-9
Chapter 2 Progressive renal function loss, a straight line? Longitudinal eGFR 19 trajectories in patients with and without type 2 diabetes and nephropathy American Journal of Kidney Diseases, In Press
Chapter 3 Slope of glomerular filtration rate as clinical trial end point 46 Submitted
Chapter 4 Estimated GFR decline as a surrogate end point for kidney failure 59 American Journal of Kidney Diseases 2014 Feb;63(2):244-50
Chapter 5 Is chronic dialysis the right hard renal end point to evaluate 80 renoprotective drug effects?
Clinical Journal of the American Society of Nephrology, In Press
Chapter 6 Summary and future perspectives 99
Nederlandse samenvatting en toekomstperspectief 107
Acknowledgments 116 Curriculum Vitae 120 9 21 47 61 83 103 111 121 126 125
___________________________________________________________________________
Chapter 1
Introduction and aim
Adapted from: Current Opinion in Nephrology and Hypertension 2015 May;24(3):284-9
